JP2017513887A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017513887A5 JP2017513887A5 JP2016564057A JP2016564057A JP2017513887A5 JP 2017513887 A5 JP2017513887 A5 JP 2017513887A5 JP 2016564057 A JP2016564057 A JP 2016564057A JP 2016564057 A JP2016564057 A JP 2016564057A JP 2017513887 A5 JP2017513887 A5 JP 2017513887A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- cycloalkyl
- haloalkyl
- alkoxy
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 170
- 125000003545 alkoxy group Chemical group 0.000 claims 44
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 claims 43
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 41
- 125000004093 cyano group Chemical group *C#N 0.000 claims 40
- 229910052736 halogen Inorganic materials 0.000 claims 38
- 150000002367 halogens Chemical class 0.000 claims 38
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 34
- 150000003839 salts Chemical class 0.000 claims 34
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 28
- 125000003118 aryl group Chemical group 0.000 claims 28
- -1 2 -cyclopropyl Chemical group 0.000 claims 27
- 229910052799 carbon Inorganic materials 0.000 claims 26
- 150000001875 compounds Chemical class 0.000 claims 24
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 23
- 208000010877 cognitive disease Diseases 0.000 claims 21
- 125000001424 substituent group Chemical group 0.000 claims 19
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 16
- 229910052757 nitrogen Inorganic materials 0.000 claims 16
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims 15
- 208000028698 Cognitive impairment Diseases 0.000 claims 14
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 13
- 125000001188 haloalkyl group Chemical group 0.000 claims 13
- 125000000753 cycloalkyl group Chemical group 0.000 claims 12
- 229910052739 hydrogen Inorganic materials 0.000 claims 12
- 125000004438 haloalkoxy group Chemical group 0.000 claims 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 10
- 201000000980 schizophrenia Diseases 0.000 claims 9
- 208000011117 substance-related disease Diseases 0.000 claims 9
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims 8
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 8
- 125000003342 alkenyl group Chemical group 0.000 claims 7
- 229910052760 oxygen Inorganic materials 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 229910052717 sulfur Inorganic materials 0.000 claims 7
- 208000024827 Alzheimer disease Diseases 0.000 claims 6
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 6
- 208000005793 Restless legs syndrome Diseases 0.000 claims 6
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 claims 6
- 230000001684 chronic effect Effects 0.000 claims 6
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 6
- 125000005843 halogen group Chemical group 0.000 claims 6
- 208000024714 major depressive disease Diseases 0.000 claims 6
- 208000027061 mild cognitive impairment Diseases 0.000 claims 6
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 5
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 5
- YSEAGKXERZRQSR-UHFFFAOYSA-N CC1=C(C(=NC=N1)C#N)C1=C(C=C(C=C1)OC=1N=CC=C2C1SC=C2)C Chemical compound CC1=C(C(=NC=N1)C#N)C1=C(C=C(C=C1)OC=1N=CC=C2C1SC=C2)C YSEAGKXERZRQSR-UHFFFAOYSA-N 0.000 claims 4
- KKNLJIKADMZRDL-UHFFFAOYSA-N CN1C(NC(C(=C1C1=C(C=C(C=C1)OC=1C2=C(N=CN1)C=CS2)C)C)=O)=O Chemical compound CN1C(NC(C(=C1C1=C(C=C(C=C1)OC=1C2=C(N=CN1)C=CS2)C)C)=O)=O KKNLJIKADMZRDL-UHFFFAOYSA-N 0.000 claims 4
- 206010012289 Dementia Diseases 0.000 claims 4
- 201000001880 Sexual dysfunction Diseases 0.000 claims 4
- 125000004432 carbon atom Chemical group C* 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 125000006413 ring segment Chemical group 0.000 claims 4
- 231100000872 sexual dysfunction Toxicity 0.000 claims 4
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 claims 3
- 206010065040 AIDS dementia complex Diseases 0.000 claims 3
- 208000019901 Anxiety disease Diseases 0.000 claims 3
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 3
- 208000020925 Bipolar disease Diseases 0.000 claims 3
- 208000032841 Bulimia Diseases 0.000 claims 3
- 206010006550 Bulimia nervosa Diseases 0.000 claims 3
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 claims 3
- 206010013654 Drug abuse Diseases 0.000 claims 3
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 3
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims 3
- 208000023105 Huntington disease Diseases 0.000 claims 3
- 206010024264 Lethargy Diseases 0.000 claims 3
- 208000009829 Lewy Body Disease Diseases 0.000 claims 3
- 201000002832 Lewy body dementia Diseases 0.000 claims 3
- 208000018737 Parkinson disease Diseases 0.000 claims 3
- 206010034158 Pathological gambling Diseases 0.000 claims 3
- 201000009916 Postpartum depression Diseases 0.000 claims 3
- 206010039966 Senile dementia Diseases 0.000 claims 3
- 206010040108 Serotonin syndrome Diseases 0.000 claims 3
- 206010041250 Social phobia Diseases 0.000 claims 3
- 206010041349 Somnolence Diseases 0.000 claims 3
- 208000000323 Tourette Syndrome Diseases 0.000 claims 3
- 208000016620 Tourette disease Diseases 0.000 claims 3
- 239000005557 antagonist Substances 0.000 claims 3
- 230000036506 anxiety Effects 0.000 claims 3
- 125000004104 aryloxy group Chemical group 0.000 claims 3
- 208000029560 autism spectrum disease Diseases 0.000 claims 3
- 230000001149 cognitive effect Effects 0.000 claims 3
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 3
- 206010013663 drug dependence Diseases 0.000 claims 3
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 3
- 206010025482 malaise Diseases 0.000 claims 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 3
- 208000022821 personality disease Diseases 0.000 claims 3
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 3
- 230000000698 schizophrenic effect Effects 0.000 claims 3
- 208000012672 seasonal affective disease Diseases 0.000 claims 3
- 208000019116 sleep disease Diseases 0.000 claims 3
- 201000009032 substance abuse Diseases 0.000 claims 3
- 231100000736 substance abuse Toxicity 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- 238000002560 therapeutic procedure Methods 0.000 claims 3
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 claims 2
- 125000006582 (C5-C6) heterocycloalkyl group Chemical group 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- ZDCVIKLPOZFEOR-UHFFFAOYSA-N CC1=NC=NC(=C1C1=C(C#N)C=C(C=C1)OC=1N=CC=C2C1SC=C2)C Chemical compound CC1=NC=NC(=C1C1=C(C#N)C=C(C=C1)OC=1N=CC=C2C1SC=C2)C ZDCVIKLPOZFEOR-UHFFFAOYSA-N 0.000 claims 2
- LENPHRQYTMJQRF-UHFFFAOYSA-N ClC=1C=C(OC=2C3=C(N=CN2)C=CS3)C=CC1C=1C(=NC=NC1C)C Chemical compound ClC=1C=C(OC=2C3=C(N=CN2)C=CS3)C=CC1C=1C(=NC=NC1C)C LENPHRQYTMJQRF-UHFFFAOYSA-N 0.000 claims 2
- 208000010228 Erectile Dysfunction Diseases 0.000 claims 2
- 208000019695 Migraine disease Diseases 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 206010043118 Tardive Dyskinesia Diseases 0.000 claims 2
- 201000004810 Vascular dementia Diseases 0.000 claims 2
- 230000007000 age related cognitive decline Effects 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 229910052801 chlorine Inorganic materials 0.000 claims 2
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims 2
- 238000002651 drug therapy Methods 0.000 claims 2
- 230000002996 emotional effect Effects 0.000 claims 2
- 229910052731 fluorine Inorganic materials 0.000 claims 2
- 125000004428 fluoroalkoxy group Chemical group 0.000 claims 2
- 125000002883 imidazolyl group Chemical group 0.000 claims 2
- 201000001881 impotence Diseases 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 206010027599 migraine Diseases 0.000 claims 2
- 125000002098 pyridazinyl group Chemical group 0.000 claims 2
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 claims 2
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 125000006568 (C4-C7) heterocycloalkyl group Chemical group 0.000 claims 1
- AXLAIAASHKOILK-UHFFFAOYSA-N 1,5-dimethyl-6-(2-methyl-4-thieno[2,3-c]pyridin-7-yloxyphenyl)pyrazin-2-one Chemical compound CN1C(C=NC(=C1C1=C(C=C(C=C1)OC=1N=CC=C2C1SC=C2)C)C)=O AXLAIAASHKOILK-UHFFFAOYSA-N 0.000 claims 1
- 125000005955 1H-indazolyl group Chemical group 0.000 claims 1
- PUYOAVGNCWPANW-UHFFFAOYSA-N 2-methylpropyl 4-aminobenzoate Chemical compound CC(C)COC(=O)C1=CC=C(N)C=C1 PUYOAVGNCWPANW-UHFFFAOYSA-N 0.000 claims 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- BSJATJKAHSPIPP-UHFFFAOYSA-N CC1=NC=NC(=C1C1=C(C=C(OC2=NC=CC3=C2SC=N3)C=C1)C)C Chemical compound CC1=NC=NC(=C1C1=C(C=C(OC2=NC=CC3=C2SC=N3)C=C1)C)C BSJATJKAHSPIPP-UHFFFAOYSA-N 0.000 claims 1
- XWQYZFQKYDPKJA-UHFFFAOYSA-N CC1=NC=NC(=C1C1=C(C=C(OC=2N=CC=C3C2OC=C3)C=C1)C)C Chemical compound CC1=NC=NC(=C1C1=C(C=C(OC=2N=CC=C3C2OC=C3)C=C1)C)C XWQYZFQKYDPKJA-UHFFFAOYSA-N 0.000 claims 1
- YYUPYYFUYVOUHE-UHFFFAOYSA-N CC1=NC=NC(=C1C1=C(C=C(OC=2N=CC=C3C2SC=C3)C=C1)C)C Chemical compound CC1=NC=NC(=C1C1=C(C=C(OC=2N=CC=C3C2SC=C3)C=C1)C)C YYUPYYFUYVOUHE-UHFFFAOYSA-N 0.000 claims 1
- GYXIMCNXDBRESN-UHFFFAOYSA-N CC=1C(NN=C(C1C1=C(C=C(C=C1)OC1=NC=CC2=C1SC=N2)C)C)=O Chemical compound CC=1C(NN=C(C1C1=C(C=C(C=C1)OC1=NC=CC2=C1SC=N2)C)C)=O GYXIMCNXDBRESN-UHFFFAOYSA-N 0.000 claims 1
- JJDMRILUIZQVDS-UHFFFAOYSA-N CC=1C(NN=C(C1C1=C(C=C(C=C1)OC=1N=CC=C2C1SN=C2)C)C)=O Chemical compound CC=1C(NN=C(C1C1=C(C=C(C=C1)OC=1N=CC=C2C1SN=C2)C)C)=O JJDMRILUIZQVDS-UHFFFAOYSA-N 0.000 claims 1
- YMMZJZWKLWMPLI-UHFFFAOYSA-N CC=1C(NN=C(C1C1=CC=C(C=C1)OC1=NC=CC2=C1SC=N2)C)=O Chemical compound CC=1C(NN=C(C1C1=CC=C(C=C1)OC1=NC=CC2=C1SC=N2)C)=O YMMZJZWKLWMPLI-UHFFFAOYSA-N 0.000 claims 1
- SXKRKDRCMOQQSU-UHFFFAOYSA-N CC=1C(NN=C(C1C1=CC=C(C=C1)OC=1C2=C(N=CN1)C=CS2)C)=O Chemical compound CC=1C(NN=C(C1C1=CC=C(C=C1)OC=1C2=C(N=CN1)C=CS2)C)=O SXKRKDRCMOQQSU-UHFFFAOYSA-N 0.000 claims 1
- RCXHRNVSCIHDCF-UHFFFAOYSA-N CN1C(C=NC(=C1C1=C(C=C(C=C1)OC=1C2=C(N=CN1)C=CS2)C)C)=O Chemical compound CN1C(C=NC(=C1C1=C(C=C(C=C1)OC=1C2=C(N=CN1)C=CS2)C)C)=O RCXHRNVSCIHDCF-UHFFFAOYSA-N 0.000 claims 1
- 206010006895 Cachexia Diseases 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- ICKLWCYUCOGXMF-UHFFFAOYSA-N ClC=1C=C(OC=2N=CC=C3C2SC=C3)C=CC1C=1C(=NC=NC1C)C Chemical compound ClC=1C=C(OC=2N=CC=C3C2SC=C3)C=CC1C=1C(=NC=NC1C)C ICKLWCYUCOGXMF-UHFFFAOYSA-N 0.000 claims 1
- 208000012661 Dyskinesia Diseases 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010021036 Hyponatraemia Diseases 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000007950 Ocular Hypotension Diseases 0.000 claims 1
- 206010030113 Oedema Diseases 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 206010038540 Renal tubular necrosis Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 125000005873 benzo[d]thiazolyl group Chemical group 0.000 claims 1
- 229910052794 bromium Inorganic materials 0.000 claims 1
- 230000006999 cognitive decline Effects 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000008451 emotion Effects 0.000 claims 1
- 125000005347 halocycloalkyl group Chemical group 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 201000003631 narcolepsy Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 230000002980 postoperative effect Effects 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 125000000168 pyrrolyl group Chemical group 0.000 claims 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 0 *c1c(*)c(*)c(*)c(*)c1* Chemical compound *c1c(*)c(*)c(*)c(*)c1* 0.000 description 3
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461984070P | 2014-04-25 | 2014-04-25 | |
| US61/984,070 | 2014-04-25 | ||
| PCT/IB2015/052594 WO2015162515A1 (en) | 2014-04-25 | 2015-04-09 | Heteroaromatic compounds and their use as dopamine d1 ligands |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017513887A JP2017513887A (ja) | 2017-06-01 |
| JP2017513887A5 true JP2017513887A5 (enExample) | 2017-07-13 |
| JP6190076B2 JP6190076B2 (ja) | 2017-08-30 |
Family
ID=53002687
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016564057A Expired - Fee Related JP6190076B2 (ja) | 2014-04-25 | 2015-04-09 | 複素芳香族化合物およびそのドーパミンｄ１リガンドとしての使用 |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US9688698B2 (enExample) |
| EP (1) | EP3134087B1 (enExample) |
| JP (1) | JP6190076B2 (enExample) |
| KR (1) | KR20160142401A (enExample) |
| CN (1) | CN106232118A (enExample) |
| AP (1) | AP2016009464A0 (enExample) |
| AU (1) | AU2015249496A1 (enExample) |
| BR (1) | BR112016023623A2 (enExample) |
| CA (1) | CA2946471C (enExample) |
| CL (1) | CL2016002678A1 (enExample) |
| CR (1) | CR20160493A (enExample) |
| CU (1) | CU20160155A7 (enExample) |
| DO (1) | DOP2016000290A (enExample) |
| EA (1) | EA201691831A1 (enExample) |
| EC (1) | ECSP16090804A (enExample) |
| IL (1) | IL247849A0 (enExample) |
| MD (1) | MD20160112A2 (enExample) |
| MX (1) | MX2016013968A (enExample) |
| NI (1) | NI201600160A (enExample) |
| PE (1) | PE20170008A1 (enExample) |
| PH (1) | PH12016501863A1 (enExample) |
| SG (1) | SG11201607990QA (enExample) |
| SV (1) | SV2016005306A (enExample) |
| TN (1) | TN2016000452A1 (enExample) |
| TW (1) | TWI553011B (enExample) |
| WO (1) | WO2015162515A1 (enExample) |
| ZA (1) | ZA201606716B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015162516A1 (en) | 2014-04-25 | 2015-10-29 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine d1 ligands |
| EP3134405B1 (en) | 2014-04-25 | 2019-08-28 | Pfizer Inc | Heteroaromatic compounds and their use as dopamine d1 ligands |
| CA2946990A1 (en) | 2014-04-28 | 2015-11-05 | Pfizer Inc. | Heterocyclic compounds and their use as dopamine d1 ligands |
| US9856263B2 (en) | 2014-04-28 | 2018-01-02 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine D1 ligands |
| KR20190067788A (ko) | 2016-11-02 | 2019-06-17 | 얀센 파마슈티카 엔.브이. | Pde2 억제제로서의 [1,2,4]트리아졸로[1,5-a]피리미딘 화합물 |
| UA125302C2 (uk) * | 2016-11-02 | 2022-02-16 | Янссен Фармацевтика Нв | Похідні [1,2,4]триазоло[1,5-a]піримідину як інгібітори pde2 |
| AR116635A1 (es) | 2018-10-15 | 2021-05-26 | Servier Lab | Proceso para la síntesis de derivados de piperazinil-etoxi-bromofenilo y su aplicación en la producción de compuestos que los contienen |
| EP3870292A4 (en) | 2018-10-26 | 2022-11-09 | The Research Foundation for The State University of New York | COMBINATION OF SEROTONIN-SPECIFIC RESUPPUT INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA |
| CN117126176B (zh) * | 2023-08-21 | 2026-01-30 | 常州大学 | 一种噻吩并嘧啶类化合物及其作为多巴胺d2受体别构拮抗剂的应用 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5681941A (en) | 1990-01-11 | 1997-10-28 | Isis Pharmaceuticals, Inc. | Substituted purines and oligonucleotide cross-linking |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| BR9101256A (pt) | 1990-03-30 | 1991-11-05 | Dowelanco | Composto,composicao fungicida,processo fungicida,composicao inseticida ou acaricida e processo inseticida ou acaricida |
| US5322847A (en) | 1992-11-05 | 1994-06-21 | Pfizer Inc. | Azabenzimidazoles in the treatment of asthma, arthritis and related diseases |
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| AR004010A1 (es) | 1995-10-11 | 1998-09-30 | Glaxo Group Ltd | Compuestos heterociclicos |
| ZA971896B (en) | 1996-03-26 | 1998-09-07 | Du Pont Merck Pharma | Aryloxy-and arythio-fused pyridines and pyrimidines and derivatives |
| WO2000035298A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing gum containing medicament active agents |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| US6232320B1 (en) | 1998-06-04 | 2001-05-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
| US6995171B2 (en) | 2001-06-21 | 2006-02-07 | Agouron Pharmaceuticals, Inc. | Bicyclic pyrimidine and pyrimidine derivatives useful as anticancer agents |
| US20030187026A1 (en) | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
| BR0308162A (pt) | 2002-03-01 | 2004-12-07 | Pfizer | Derivados de indolil-uréia de tienopiridinas úteis como agentes antiangiogênicos e métodos para o seu uso |
| US20050284101A1 (en) * | 2004-06-24 | 2005-12-29 | Brandes Donald J | Method and apparatus for assembling strong, lightweight thermal panel and insulated building structure |
| US20050239806A1 (en) | 2004-01-13 | 2005-10-27 | Ambit Biosciences Corporation | Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases |
| WO2005110410A2 (en) * | 2004-05-14 | 2005-11-24 | Abbott Laboratories | Kinase inhibitors as therapeutic agents |
| MEP8409A (en) | 2004-06-02 | 2011-12-20 | Fused heterocyclic compound | |
| JP5368701B2 (ja) | 2004-07-02 | 2013-12-18 | エクセリクシス、インコーポレイテッド | ｃ−Ｍｅｔモジュレーター及び使用方法 |
| GB0502573D0 (en) | 2005-02-08 | 2005-03-16 | Topotarget As | Therapeutic compounds |
| EP1877411B9 (en) | 2005-05-05 | 2012-08-29 | Ardea Biosciences, Inc. | Diaryl-purine, azapurines and -deazapurines as non-nucleoside reverse transcriptase inhibitors for treatment of hiv |
| NZ564283A (en) | 2005-05-20 | 2011-07-29 | Methylgene Inc | Inhibitors of VEGF receptor and HGF receptor signaling |
| EP1746096A1 (en) * | 2005-07-15 | 2007-01-24 | 4Sc Ag | 2-Arylbenzothiazole analogues and uses thereof in the treatment of cancer |
| EP1989211A2 (en) | 2006-01-30 | 2008-11-12 | Array Biopharma, Inc. | Heterobicyclic thiophene compounds for the treatment of cancer |
| CN101466716A (zh) | 2006-04-07 | 2009-06-24 | 德维洛根股份公司 | 用于药物组合物的具有mnkl/mnk2抑制活性的噻吩并嘧啶 |
| EP3187866B1 (en) | 2007-12-10 | 2019-04-17 | Ascensia Diabetes Care Holdings AG | Electrochemical test sensor |
| ES2389752T3 (es) * | 2007-12-14 | 2012-10-31 | Ardea Biosciences, Inc. | Inhibidores de la transcriptasa inversa |
| US9271962B2 (en) | 2008-03-17 | 2016-03-01 | Northeastern University | Inhibitors of fatty acid amide hydrolase and monoacylglycerol lipase for modulation of cannabinoid receptors |
| CA2722220C (en) | 2008-04-30 | 2016-06-07 | National Health Research Institutes | Fused bicyclic pyrimidine compounds as aurora kinase inhibitors |
| US8946239B2 (en) | 2008-07-10 | 2015-02-03 | Duquesne University Of The Holy Spirit | Substituted pyrrolo, -furano, and cyclopentylpyrimidines having antimitotic and/or antitumor activity and methods of use thereof |
| TWI461425B (zh) | 2009-02-19 | 2014-11-21 | Janssen Pharmaceuticals Inc | 作為伽瑪分泌酶調節劑之新穎經取代的苯并唑、苯并咪唑、唑并吡啶及咪唑并吡啶衍生物類 |
| WO2010118367A2 (en) | 2009-04-10 | 2010-10-14 | Progenics Pharmaceuticals, Inc. | Antiviral pyrimidines |
| WO2011032050A2 (en) | 2009-09-11 | 2011-03-17 | Trius Therapeutics, Inc. | Gyrase inhibitors |
| AR079705A1 (es) | 2009-12-23 | 2012-02-15 | Biocryst Pharm Inc | Compuestos heterociclicos como inhibidores de janus quinasa |
| KR101483215B1 (ko) | 2010-01-29 | 2015-01-16 | 한미약품 주식회사 | 단백질 키나아제 저해활성을 갖는 비시클릭 헤테로아릴 유도체 |
| CN102558147B (zh) * | 2010-12-23 | 2014-09-17 | 江苏先声药物研究有限公司 | 化合物、制备方法及应用 |
| PE20140928A1 (es) | 2011-04-21 | 2014-08-24 | Origenis Gmbh | Pirazolo[4,3-d]pirimidinas utiles como inhibidores de cinasas |
| DE102011111400A1 (de) | 2011-08-23 | 2013-02-28 | Merck Patent Gmbh | Bicyclische heteroaromatische Verbindungen |
| JP5823657B1 (ja) * | 2012-11-08 | 2015-11-25 | ファイザー・インク | ドーパミンｄ１リガンドとしての複素芳香族化合物 |
| SG11201502763VA (en) * | 2012-11-08 | 2015-05-28 | Pfizer | Heteroaromatic compounds and their use as dopamine d1 ligands |
| JP6026024B2 (ja) | 2013-06-27 | 2016-11-16 | ファイザー・インク | 複素芳香族化合物およびそのドーパミンｄ１リガンドとしての使用 |
| WO2015162516A1 (en) * | 2014-04-25 | 2015-10-29 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine d1 ligands |
-
2015
- 2015-04-09 CR CR20160493A patent/CR20160493A/es unknown
- 2015-04-09 JP JP2016564057A patent/JP6190076B2/ja not_active Expired - Fee Related
- 2015-04-09 TN TN2016000452A patent/TN2016000452A1/en unknown
- 2015-04-09 BR BR112016023623A patent/BR112016023623A2/pt not_active IP Right Cessation
- 2015-04-09 MX MX2016013968A patent/MX2016013968A/es unknown
- 2015-04-09 PE PE2016002125A patent/PE20170008A1/es not_active Application Discontinuation
- 2015-04-09 SG SG11201607990QA patent/SG11201607990QA/en unknown
- 2015-04-09 WO PCT/IB2015/052594 patent/WO2015162515A1/en not_active Ceased
- 2015-04-09 AP AP2016009464A patent/AP2016009464A0/en unknown
- 2015-04-09 CN CN201580020992.7A patent/CN106232118A/zh active Pending
- 2015-04-09 EA EA201691831A patent/EA201691831A1/ru unknown
- 2015-04-09 EP EP15718387.2A patent/EP3134087B1/en active Active
- 2015-04-09 AU AU2015249496A patent/AU2015249496A1/en not_active Abandoned
- 2015-04-09 MD MDA20160112A patent/MD20160112A2/ro not_active Application Discontinuation
- 2015-04-09 CA CA2946471A patent/CA2946471C/en not_active Expired - Fee Related
- 2015-04-09 KR KR1020167032876A patent/KR20160142401A/ko not_active Withdrawn
- 2015-04-22 TW TW104112873A patent/TWI553011B/zh not_active IP Right Cessation
- 2015-04-23 US US14/694,039 patent/US9688698B2/en active Active
-
2016
- 2016-09-15 IL IL247849A patent/IL247849A0/en unknown
- 2016-09-22 PH PH12016501863A patent/PH12016501863A1/en unknown
- 2016-09-28 ZA ZA2016/06716A patent/ZA201606716B/en unknown
- 2016-10-20 CL CL2016002678A patent/CL2016002678A1/es unknown
- 2016-10-21 NI NI201600160A patent/NI201600160A/es unknown
- 2016-10-24 CU CUP2016000155A patent/CU20160155A7/es unknown
- 2016-10-25 SV SV2016005306A patent/SV2016005306A/es unknown
- 2016-10-25 DO DO2016000290A patent/DOP2016000290A/es unknown
- 2016-11-25 EC ECIEPI201690804A patent/ECSP16090804A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017513887A5 (enExample) | ||
| TWI695002B (zh) | 用於治療發炎病症之新穎化合物及彼等之醫藥組合物 | |
| RU2015115400A (ru) | Гетероароматические соединения и их применение в качестве допаминовых D1 лигантов | |
| EA025520B1 (ru) | N-(ГЕТЕРО)АРИЛПИРРОЛИДИНОВЫЕ ПРОИЗВОДНЫЕ ПИРАЗОЛ-4-ИЛ-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ И ПИРРОЛ-3-ИЛ-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-КИНАЗЫ | |
| EP2920177A1 (en) | Compounds and compositions for the treatment of parasitic diseases | |
| JP2013522354A5 (enExample) | ||
| RU2016141645A (ru) | ИНГИБИТОРЫ TrkA КИНАЗЫ, ОСНОВАННЫЕ НА НИХ КОМПОЗИЦИИ И СПОСОБЫ | |
| JP2016511258A5 (enExample) | ||
| KR20160023684A (ko) | 신규한 바이사이클릭 브로모도메인 억제제 | |
| RU2016130932A (ru) | Производные хинолона как ингибиторы рецептора фактора роста фибробластов | |
| JP2016523270A5 (enExample) | ||
| JP2019503337A5 (enExample) | ||
| JP2015537017A5 (enExample) | ||
| JP2016520118A5 (enExample) | ||
| JP2013505930A5 (enExample) | ||
| JP2017501983A5 (enExample) | ||
| CA3136324A1 (en) | Acss2 inhibitors and methods of use thereof | |
| JP2013533868A (ja) | タンパク質チロシンキナーゼ阻害剤としての新規ホモピペラジン誘導体およびそれらの医薬使用 | |
| JP2019512535A5 (enExample) | ||
| JP2020526549A5 (enExample) | ||
| JP2016540803A5 (enExample) | ||
| RU2018141084A (ru) | Соединения тетрагидропиримидодиазепина и дигидропиридодиазепина для лечения боли и связанных с болью состояний | |
| WO2012077031A1 (en) | Substituted imidazoquinoline derivatives | |
| RU2017134107A (ru) | Триазолилпиримидиноновые соединения в качестве ингибиторов pde2 | |
| JP2018512062A5 (enExample) |